Laetrile is a diglucoside with a cyanide radical that is highly “bio-accessible”. It penetrates through the cellular membrane, reaching high intra-cellular concentrations easily.
In high doses this cyanide radical can be toxic. However, for therapeut purposes laetrile is administered in very low doses and is neutralized by the enzyme rhodenase which is present in healthy cells of our body. This enzyme prevents laetrile from releasing cyanide. Laetrile serves as glucose to healthy cells, which provides energy when metabolized.
Malignant cells do not contain the rhodenase enzyme. In the absence of rhodenase, laetrile is activated and the cyanide radical is released within malignant cells and this action has been shown to contribute to tumor destruction. An additional benefit of laetrile therapy is the fact that as laetrile attacks unhealthy cells, it transforms into a salicilate (like aspirin) and contributes to pain control.
Research studies suggest that laetrile affects cancerous cells and leaves normal cells unharmed. During many years of clinical experience laetrile has been shown to have anti-cancer properties without the toxic side effects typically encountered with chemotherapy.
Personalized treatment protocols of the Issels Treatment Center integrate laetrile when indicated.
DISCLAIMER: No claim is made that patients with similar diagnosis and/or treatment/s will respond to the same extent as the patients shown. All testimonials had been provided voluntarily to share their experience with the Issels Treatment and their state of health at the time. Some may have passed away due to age or disease. None of these patients received compensation or are related to the Issels Treatment Centers.